University of Toledo   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Toledo OH United States (1872)

Organization Overview

First Clinical Trial
2003
NCT00860340
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

John Nemunaitis, MD | Krishna Reddy, MD, PhD | Professor, University of Toledo | The University of Toledo | The University of Toledo Medical Center 3000 Arlington Avenue, Toledo OH 43614 USA | University of Toledo | University of Toledo College of Medicine | University of Toledo Health Science Campus | University of Toledo-HSC | University of Toledo, HSC | University of Toledo Medical Center | UTMC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cardiovascular Diseases (Phase 3)

Colic (Phase 2)

Hypertension, Renovascular (Phase 3)

Infections (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Lung Neoplasms (Phase 2)

Migraine Disorders (Phase 4)

Muscle Hypotonia (Phase 4)

Pancreatic Neoplasms (Phase 1)

Pneumococcal Infections (Phase 1)

Renal Artery Obstruction (Phase 3)

Respiratory Tract Infections (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 24